Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

This study has been completed.
Information provided by (Responsible Party):
Exelixis Identifier:
First received: July 12, 2009
Last updated: February 18, 2015
Last verified: February 2015